OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel ...
StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note issued to investors on Monday morning. The brokerage issued a hold rating on the ...
The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The "Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025" report ...
Reports Q4 revenue $69.1M, consensus $61.58M. “The significant progress we and our partners achieved throughout 2024 has formed a strong ...
Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million ––Q4 Total Revenue Grew 114% ...
Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.
A new generation of therapeutics looks beyond simply reengineering the gut microbiome to exploiting multiple pathways for novel microbiome and microbial applications.
DNA repair proteins act like the body's editors, constantly finding and reversing damage to our genetic code. Researchers ...
Investor's Business Daily on MSN18h
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...
Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a ...
Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc , a global healthcare intelligence and clinical research organization, today announce a partnership to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback